Live or Die: Choice Mechanisms in Stressed CellsView this Special Issue
Research Article | Open Access
Salvatore Rizza, Claudia Cirotti, Costanza Montagna, Simone Cardaci, Claudia Consales, Mauro Cozzolino, Maria Teresa Carrì, Francesco Cecconi, Giuseppe Filomeni, "S-Nitrosoglutathione Reductase Plays Opposite Roles in SH-SY5Y Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis", Mediators of Inflammation, vol. 2015, Article ID 536238, 12 pages, 2015. https://doi.org/10.1155/2015/536238
S-Nitrosoglutathione Reductase Plays Opposite Roles in SH-SY5Y Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Oxidative and nitrosative stresses have been reported as detrimental phenomena concurring to the onset of several neurodegenerative diseases. Here we reported that the ectopic modulation of the denitrosylating enzyme S-nitrosoglutathione reductase (GSNOR) differently impinges on the phenotype of two SH-SY5Y-based in vitro models of neurodegeneration, namely, Parkinson’s disease (PD) and familial amyotrophic lateral sclerosis (fALS). In particular, we provide evidence that GSNOR-knocking down protects SH-SY5Y against PD toxins, while, by contrast, its upregulation is required for G93A-SOD1 expressing cells resistance to NO-releasing drugs. Although completely opposite, both conditions are characterized by Nrf2 localization in the nuclear compartment: in the first case induced by GSNOR silencing, while in the second one underlying the antinitrosative response. Overall, our results demonstrate that GSNOR expression has different effect on neuronal viability in dependence on the stimulus applied and suggest that GSNOR could be a responsive gene downstream of Nrf2 activation.
Oxidative and nitrosative stress has been copiously reported to play a pivotal role in the onset of neurodegenerative diseases [1, 2]. Both endogenous and exogenous sources of nitrooxidative stress, such as mitochondria  and immune cells  that produce reactive oxygen species (ROS) or reactive nitrogen species (RNS) deriving from nitric oxide (NO), deeply contribute to the persistence of noxious conditions affecting neuron viability. Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) are among the neurodegenerative disorders in which nitrooxidative stress has been particularly reported being implied in the loss of specific neuronal populations.
PD is a neurodegenerative disorder that leads to a progressive loss of dopaminergic neurons. The mechanisms underlying this phenomenon are not completely clarified. However, mitochondrial damages (mainly those affecting complex I of the respiratory chain), failure in proteins, and organelles quality control as well as oxidative and nitrosative stress have been suggested to be implicated in the pathogenesis of PD . Several are the mutations associated with the family forms of PD . Many of them affect specific proteins, for example, PINK1, Parkin, and DJ-1. In particular, DJ-1 has been implicated in the protection against oxidative insults as it interferes with the production of mitochondrial ROS, and it has been reported to be undergoing activation by S-nitrosylation processes [7–9]. Moreover, the existence of a signaling axis involving DJ-1 as upstream modulator of Nrf2 (NE-F2-related factor-2) [10, 11], the transcription factor known as one of the master regulators of redox homeostasis, has recently been demonstrated, suggesting that DJ-1 may act in different ways in order to counteract oxidative stress.
ALS is a multifactorial disease caused by motor neuron degeneration that can be divided into a sporadic (90% of the cases) and a familial form (fALS) whose 20% of mutations (2% of total ALS cases) map throughout the SOD1 gene (coding the Cu, Zn superoxide dismutase) [12, 13]. More than 100 point mutations in SOD1 gene are associated with fALS cases, with some of them affecting its antioxidant activity. One of the most studied SOD1 mutations is the G93A substitution which results in the aggregation of the mutant forms, being, in such a way, detrimental for mitochondrial homeostasis and motor neuron survival. Another common feature of ALS is the chronic inflammatory response activated in the cells surrounding motor neurons (astrocytes and microglia) that leads to the production of cytokines and NO [14–16].
S-Nitrosylation represents one of the main NO-mediated posttranslational modifications . It is based on the attachment of an NO moiety to the thiol group (-SH) of cysteine residues, resulting in the formation of low (amino acids and peptides) and high molecular weight (proteins) S-nitrosothiols (SNOs). Although NO could modulate either neuronal viability or death, the role of neuronal S-nitrosothiols (SNOs) in the etiopathogenesis of neurodegenerative diseases remains to be fully elucidated yet. Protein aggregates found in brains from PD and ALS patients show a great abundance of nitrated/S-nitrosylated proteins, suggesting that SNOs are involved in the pathogenesis and/or in the neuronal defense responses. However, recent results  indicate that NO is a potent antioxidant agent that reduces oxidative stress in the central nervous system, such as by increasing the antioxidant capacity of reduced glutathione (GSH) through the formation of S-nitrosoglutathione (GSNO), which is a 100-fold more potent antioxidant with respect to GSH.
It has been reported that class III alcohol dehydrogenase  also known as S-nitrosoglutathione reductase (GSNOR) catalyzes the degradation of GSNO, thus regulating the amount of SNOs and NO bioactivity. Although GSNOR-deficient (KO) mice are viable and fertile, they show some pathological phenotypes, many of which related to aging, such as (i) compromised lymphocytes development ; (ii) high morbidity and mortality upon endotoxic shock ; (iii) DNA damage accumulation; (iv) high probability to develop hepatocellular carcinoma [21, 22]; (v) early signs of peripheral neuropathy . Altogether, this evidence indicates that (i) excessive S-nitrosylation negatively impacts on cell physiology and (ii) GSNOR acts as the principal molecular modulator underneath. GSNOR, in fact, is the best characterized denitrosylating enzyme evolutionarily conserved from bacteria to humans , which is widely expressed in all tissues and organs. In particular, brain has been reported to express high levels of GSNOR . However, any alteration linked to GSNOR deficiency in nervous system has never been reported so far.
Based on the evidence that GSNOR deficiency results in ageing-related phenotypes and that brain represents the organ mostly affected during ageing, here we have aimed at characterizing the role of GSNOR in modulating the severity of two neurodegenerative diseases, PD and fALS, taking SH-SY5Y as elective experimental system.
2. Materials and Methods
2.1. Cell Cultures
Human SH-SY5Y cells were purchased from the European Collection of Cell Culture and grown at 37°C in an atmosphere of 5% CO2. SH-SY5Y cells were cultured in DMEM-F12 containing 25 mM glucose, supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 1,000 U/mL penicillin-streptomycin. All media were from Lonza. G93A-SOD1 stably expressing SH-SY5Y cells were generated as previously reported . LowNO clone was selected from a mixed population of G93A cells subjected to repeated treatments with GSNO.
2.2. Cell Transfection with siRNAs
24 hours after plating, SH-SY5Y cells were transfected with a commercially available small interference RNA (siRNA) against GSNOR (Sigma). Control cells were transfected with a scramble siRNA duplex (siScr), which does not present homology with any other human mRNAs. In experiments aimed at downregulating DJ-1, double transfection (with both siRNAs against GSNOR and DJ-1) was carried out simultaneously.
All treatments were performed for 24 h in completed culture media. DPTA was used at a concentration of 400 μM, H2O2 at 1 mM, MPP+ at 1.25 or 2.5 mM, and 6OHDA at 50 μM. Trigonelline was preincubated for 30 min before treatments with DPTA and used at a concentration of 0.5 or 1 μM.
2.4. Analysis of Cell Death
Cell death was evaluated by direct cell count at optic microscopy upon Trypan blue staining or, cytofluorometrically, by assessing the percentages of apoptotic cells upon staining with propidium iodide.
2.5. Animal Experimentation
All mouse experiments were conducted in accordance with the European Community guidelines and with the approval of relevant national (Ministry of Health) and local (Institutional Animal Care and Use, Tor Vergata University) ethical committees. All mice employed in the experiments (wild type, G93A, and GSNOR-KO) were on C57BL/6J background. They have been raised and crossed in the indoor animal house in a 12 h light/dark cycle in a virus/antigen-free facility with controlled temperature and humidity and have been provided with water and food ad libitum. At the indicated time, mice were anesthetized with ketamine–xylazine, killed, and dissected for the different experiments. All efforts were made to minimize suffering.
2.5.1. Spinal Cords
Spinal cords were collected from wild type (WT) and symptomatic (135-day-old) G93A-SOD1 mice B6.Cg-Tg(SOD1-G93A)1Gur/J (Jackson Laboratory, Bar Harbor, ME, USA) minced and lysed by 40–60 strokes in Potter-Elvehjem homogenizer and supernatants used for PSNOs detection and GSNOR activity.
Brains were collected from 2-month-old wild type (WT) and GSNOR-deficient (KO) mice. Mesencephalon (ventromedial zone) was then isolated, since it contains most of the dopaminergic cells (which are affected in PD), minced and lysed by 30–40 strokes in Potter-Elvehjem homogenizer and supernatants used for Western blot analyses.
Mouse primary cortical neurons (PCN) were obtained from cerebral cortices of E15 C57BL/6 mice (WT and GSNOR-KO) embryos. Minced cortices were digested with trypsin EDTA 0.25% at 37°C for 7 minutes. Cells were stained with 0.08% Trypan blue solution and only viable cells were counted and plated at the density of 1 × 105/cm2 onto poly-d-lysine coated multiwell plates in 25 mM glucose-containing MEM medium supplemented with 10% fetal bovine serum, 2 mM glutamine, and 0.1 mg/mL gentamicin. After 1 hour, the medium was replaced with Neurobasal medium containing antioxidant-free B27 supplement, 2 mM glutamine, and 0.1 mg/mL gentamicin. Cell cultures were kept at 37°C in a humidified atmosphere containing 5% CO2. Every 3 days, one-third of the medium was replaced up to day 7, the time at which the cells were treated.
2.6. Western Blotting
Cell or tissue were lysed or homogenized in a lysis buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP-40, and 12 mM Na-deoxycholate supplemented with protease and phosphatase inhibitors cocktail. Nuclei and cytosol were obtained as previously described . Protein concentration was determined by the Lowry protein assay. Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes that were probed with the following antibodies: anti-nNOS (Santa Cruz), anti-SOD1 (Santa Cruz), anti-LDH (Santa Cruz), anti-poly-ADP-ribose polymerase 1 (PARP1), anti-actin (Santa Cruz), anti-tubulin (Sigma), anti-GSNOR (Thermo Scientific), anti-DJ-1 (Santa Cruz), anti-AKT (Santa Cruz), anti-phospho-AKT (Santa Cruz), anti-Nrf2 (Santa Cruz), and anti-H2B (Santa Cruz). After immunostaining with appropriate secondary horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse antibodies, bands were revealed using the Amersham ECL detection system.
2.7. Detection of Oxidative Stress
2.7.1. ROS Evaluation
30 minutes before the end of the experimental time, cells were incubated with 50 μM H2-DCF at 37°C, washed, and resuspended in ice-cold PBS. The fluorescence intensities of DCF, formed by the reaction of H2-DCF with ROS, were analyzed cytofluorometrically by recording FL-1 fluorescence.
Carbonylated proteins were detected using the Oxyblot Kit (Intergen, Purchase, NY) after reaction with 2,4-dinitrophenylhydrazine (DNP) for 15 minutes at 25°C. Samples were then resolved by 10% SDS polyacrylamide gel electrophoresis and DNP-derivatized proteins identified by immunoblot using an anti-DNP antibody.
2.8. Evaluation of GSNOR Activity
2.9. Detection of S-Nitrosylated Proteins (PSNOs) and Pull-Down
S-Nitrosylation assays were performed as previously described . In particular, cells or tissues were lysed or homogenized in HEN buffer (25 mM HEPES, 50 mM NaCl, 0.1 mM EDTA1% NP-40, protease inhibitors, pH 7.4). Free cysteine residues were blocked with S-methyl methanethiosulfonate (MMTS). More specifically, 0.5–2 mg of protein samples were diluted to 1.8 mL with HEN buffer (100 mM HEPES, 1 mM EDTA, 0.1 mM neocuproine, pH 8.0). Next, 0.2 mL of 25% SDS is added along with 20 μL of 10% MMTS (to reach a final volume of 2 mL and final concentrations of 2.5% SDS and 0.1% MMTS) and incubated at 50°C in the dark for 15–20 min with frequent vortexes. Proteins were then precipitated upon incubation with acetone, resuspended in 0.24 mL HENS buffer (HEN buffer with 1% SDS), and transferred to a fresh tube containing biotin-HPDP (2.5 mg/mL) with or without sodium ascorbate (20 mM). After incubation with the HRP-conjugated streptavidin, biotinylated proteins were revealed using the Amersham ECL detection system. Ascorbate-free samples have been omitted for straightforward visualization and interpretation of data.
Once obtained, the pool of PSNOs was pulled down by incubation with streptavidin and proteins there included were revealed on SDS-PAGE upon incubation with specific primary antibody (e.g., DJ-1).
2.10. Fluorescence Microscopy
Cells were cultured on coverslips, fixed with 4% paraformaldehyde, and permeabilized. Polyclonal anti-Nrf2 and monoclonal Grp75 (Millipore) were used as primary antibodies and probed successively with the appropriate Alexa Fluor 568-conjugated secondary antibody. To visualize nuclei and the actin cytoskeleton, cells were incubated with the cell-permeable DNA-specific dye Hoechst 33342 (Calbiochem-Novabiochem) and fluorescein isothiocyanate- (FITC-) conjugated phalloidin (Invitrogen), respectively. Images were digitized with a Cool Snap video camera connected to a Nikon Eclipse TE200 fluorescence microscope.
2.11. Fluorescence Microscopy Detection of
JC-1 (Life Technologies) was added to prewarmed cell medium at the final concentration of 5 μg/mL in order to evaluate . After incubation for 10 min at 37°C, cells were washed in PBS and analyzed using a EVOS Floid Cell Imaging Station.
2.12. Data Presentation
All experiments were done at least three different times unless otherwise indicated. The results are presented as means ± SD. Statistical evaluation was conducted by ANOVA, followed by Bonferroni’s test. Comparisons were considered significant at .
3.1. GSNOR Downregulation Protects SH-SY5Y Cells from MPP+-Induced Toxicity
In order to analyze the effects of S-nitrosylation on the viability of dopaminergic cells challenged with PD toxins, we selected the SH-SY5Y cell line in which we transiently knocked down GSNOR (siGSNOR cells) (Figures 1(a) and 1(b)). We then subjected the cells to different doses of the mitochondrial toxin MPP+, used to recapitulate in vitro PD-like conditions, and we analyzed cell viability by Trypan blue staining. Dose response experiments indicted that, except for the highest dose employed (namely, 10 mM) where viability was completely compromised, siGSNOR cells were more resistant to MPP+-mediated toxicity (Figure 2(a)). Cytofluorometric analyses upon propridium iodide staining also demonstrated that the extent of Sub-G1 (apoptotic) population was lower in siGSNOR cells (Figure 2(b)) upon treatment with either 1.25 or 2.5 μM MPP+. Coherently, Western blot analyses of poly-ADP ribose polymerase 1 (PARP1) cleavage indicated that siGSNOR cells were almost unaffected by treatment with 2.5 mM MPP+ if compared with the scrambled siRNA transfected controls (siScr) (Figure 2(c)). To confirm these results, we also treated the cells with 50 μM 6-hydroxydopamine (6-OHDA), another toxin usually employed to induce PD-like cell death. As expected, results shown in Figure 2(d) confirmed that siGSNOR cells were more resistant to PD toxin mediated challenge.
3.2. GSNOR Downregulation Correlates with a General Decrease of Oxidative Stress
In order to figure out the molecular events responsible for siGSNOR cell resistance to PD toxins, we cytofluorometrically analyzed H2O2 produced in SH-SY5Y under basal conditions by means of incubations with 2′,7′-dihydrodichlorofluorescein (DCF). Figure 3(a) indicates that H2O2 production was endogenously lower in siGSNOR than siScr cells. Consistently, primary cortical neurons (PCN) obtained from GSNOR-deficient (GSNOR-KO) mice showed an endogenous production of H2O2 significantly reduced with respect to the wild type (WT) counterparts (Figure 3(b)). Dihydroethidine (DHE) staining also showed that GSNOR-KO PCN exhibited low levels of (Figure 3(c)), confirming that GSNOR depletion was associated with a general reduction of endogenous levels of ROS. These lines of evidence were in agreement with the observation that the extent of protein carbonylation measured in lysates from mesencephalon of brains obtained by GSNOR-KO mice was lower than the WT counterpart (Figure 3(d)), suggesting that GSNOR deficiency could induce an enhancement of the antioxidant defense.
3.3. GSNOR Downregulation Induces DJ-1 and Nrf2 Activation
In the search for the molecular determinants underlying the decrease of oxidative markers observed upon GSNOR downregulation or complete ablation, we focused on DJ-1, whose increased expression and S-nitrosylation have been reported playing a pivotal role in neuroprotection [9, 28, 29]. Results shown in Figure 4(a) indicate that DJ-1 was upregulated in siGSNOR SH-SY5Y cells and that this correlated with an increase in the phosphoactive form of AKT. Interestingly, total brain lysates obtained from WT and GSNOR-KO mouse brains displayed the same trend (Figure 4(b)), which was also associated with an increase of the S-nitrosylated form of DJ-1 (Figure 4(c)), suggesting that DJ-1 was upregulated and, reasonably, activated by S-nitrosylation upon GSNOR downregulation. Coherently, transfection with siRNA against DJ-1 resulted in a significant increase of MPP+-mediated toxicity in siGSNOR cells, while it seemed to be completely ineffective in siScr SH-SY5Y (Figure 4(d)).
We previously demonstrated that GSNOR-KO skeletal muscle showed an induction of Nrf2 . Moreover data from the literature show that DJ-1 is an upstream modulator of the Nrf2-mediated antioxidant response [10, 11]. Therefore, we focused on this transcription factor. Namely, we analyzed its nuclear versus cytosolic localization, which is commonly accepted as predictive sign of Nrf2 activation. Immunofluorescence analyses of PCN indicated that Nrf2 localization significantly changed from being exclusively cytosolic and axonal (WT) into predominantly nuclear (GSNOR-KO) (Figure 5(a)). Western blot analyses performed in cytosolic and nuclear fractions of both siGSNOR SH-SY5Y and GSNOR-KO brains indicated that nuclear levels of Nrf2 were higher if compared with siScr and WT controls, respectively (Figures 5(b) and 5(c)), confirming previously obtained results and reinforcing the hypothesis that Nrf2 was activated upon GSNOR downregulation. In agreement with these observations, we inhibited Nrf2 with 1 μM of its pharmacological inhibitor trigonelline and analyzed cell death. Figure 5(d) shows that preincubation with trigonelline significantly exacerbated MPP+-induced toxicity in siGSNOR cells, arguing for a role of Nrf2 in cell protection against MPP+ in conditions of nitrosative stress.
3.4. GSNOR Decrease Sensitizes G93A-Expressing Models of ALS to Nitrosative Stress
Next, we wondered to extend our analyses and figure out any role of GSNOR in neurodegenerative disturbances where NO-mediated toxicity has been frequently reported being a factor affecting neuronal viability. In particular, we focused on ALS whose progression and severity have been tightly correlated with NO overproduction and nitrosative stress. In order to verify whether excessive S-nitrosylation occurred in ALS, we initially performed biotin switch assays of S-nitrosylated proteins (PSNOs) in spinal cord of mice overexpressing the fALS associated G93A mutant form of SOD1 that we selected as in vivo elective model of ALS; Figure 6(a) shows that PSNOs levels were significantly increased in symptomatic G93A mice (135-day-old), confirming the hypothesis that ALS was accompanied by aberrant S-nitrosylation. Interestingly, spectrophotometric analyses indicated that this condition was associated with a marked decrement of GSNOR activity (Figure 6(b)), suggesting that GSNOR decrease could concur to nitrosative stress and motor neuron death observed in ALS.
Coherently, we and others had already reported that SOD1-G93A overexpression rendered SH-SY5Y cells (hereafter named G93A cells) sensitive to nitrosative stress , and during our experiments we observed that 24 h treatments with 400 μM of the NO-donor DPTA induced higher extent of apoptotic cells in G93A cells if compared with parental SH-SY5Y cells (Figure 6(c)). Interestingly, this condition was exacerbated by siRNA-induced GSNOR downregulation (Figure 6(c)), adding in such a way a further evidence that GSNOR could play a role in ALS, namely, in protecting ALS motor neurons against nitrosative stress.
3.5. GSNOR Upregulation Induces Resistance to Nitrosative Stress in G93A Cells
We then selected a clone of G93A cells that significantly upregulated GSNOR and downregulated nNOS (clone hereafter named as lowNO) (Figure 7(a)). This clone still maintained the typical phenotype of fALS mutant SOD1, such as mitochondrial fragmentation (Figure 7(b)) and depolarization (Figure 7(c)), together with an endogenous production of ROS (Figure 7(d)). However, the extent of protein carbonylation decreased in this clone (Figure 7(e)), reinforcing the idea that NO directly contributes to carbonylation.
In agreement with high GSNOR levels, we found out that the lowNO clone was highly resistant to 24 h treatment with DPTA (Figure 7(f)), indicatingthat GSNOR induction was protective against nitrosative challenge in in vitro fALS models.
3.6. Nrf2 Contributes to Antinitrosative Response
In order to characterize the GSNOR-based preconditioning response underlying lowNO clone resistance to nitrosative stress, we performed localization assays of Nrf2 by Western blot. Figure 8(a) shows that Nrf2 preferentially distributed in the nucleus of lowNO clone, arguing for Nrf2 being induced in these cells. Consistently, incubation of lowNO clone with trigonelline increased susceptibility to DPTA (Figure 8(b)), allowing the hypothesis that Nrf2 activation and GSNOR upregulation, both found in lowNO clone, were functionally correlated in mediating resistance of G93A cells to nitrosative stress.
In this work we have analyzed and characterized the role of GSNOR and S-nitrosylation in modulating phenotype severity of in vitro PD and fALS models. Despite the fact that GSNOR is the only alcohol dehydrogenase highly expressed in the central nervous system of mouse, rat, and humans , to the best of our knowledge this is the first evidence arguing for GSNOR being a crucial molecular player of neuronal homeostasis. Interestingly, here we have provided evidence that knocking down GSNOR expression results in a significant protection against PD toxins, such as MPP+ and 6OHDA. We recently demonstrated that muscles from GSNOR-KO mice show a clear fragmentation and depolarization of the mitochondrial network, which are associated with an endogenous activation of Nrf2-mediated antioxidant response . It is therefore plausible that, under these conditions, mitochondria are less affected by MPP+ and highly protected against any further production of ROS, for example, that induced by 6OHDA. From this perspective, GSNOR downregulation represents a molecular event responsible for neuronal cell adaptation against oxidative stress and a possible tool to be exploited in order to counteract PD onset and progression.
However, GSNOR downregulation should sensitize cells to nitrosative stress. This is a crucial issue if we take into account neurodegenerative diseases in which NO-mediated toxicity highly contributes to the loss of specific neuronal populations, such as motor neurons in ALS. In particular, a direct role of chronic NO-based inflammatory response activated by astrocytes and microglia has been reported in ALS as detrimental event concurring to motor neuron cell death . In agreement, we observed that in vitro models of fALS, namely, the SOD1-G93A SH-SY5Y cells, are highly susceptible to the toxicity of the NO-releasing drug DPTA, which is in line with previously published data obtained with other NO donors . In these conditions, ectopic downregulation of GSNOR expression by siRNA exacerbates NO-mediated cell death, confirming our hypothesis of a protective role of GSNOR in cells susceptible to nitrosative stress. Remarkably, in our studies we found out that G93A-SOD1 expressing mice show an increase of spinal cord PSNOs in association with a decrease of GSNOR activity. This finding suggests for the first time that GSNOR is downregulated in ALS and argues for GSNOR decrease being a new marker of ALS onset and, mainly, progression. This hypothesis is strengthened by the results obtained in the GSNOR-overexpressing lowNO G93A clone which shows resistance to DPTA, thereby indicating that S-nitrosylation is a posttranslational modification strongly implicated in driving motor neuron death response to nitrosative stress in ALS.
Interestingly, our data support the hypothesis that Nrf2 could play a pivotal role also in these conditions. In particular, we have found out that cell adaptation induced by lowNO G93A clone to survive to nitrosative stress conditions (namely, GSNOR induction combined with nNOS downregulation) is associated, at least in part, with the induction of Nrf2, as trigonelline significantly increases lowNO G93A clone sensitivity to NO.
Altogether, these results argue for Nrf2 being tightly related to GSNOR expression. In particular, while Nrf2 is activated in response to (downstream of) GSNOR depletion to protect against PD toxins-induced cell death, it could also induce (be upstream of) GSNOR transcription to preserve survival in in vitro models of fALS in conditions of nitrosative stress. A positive feedback loop between Nrf2 and GSNOR could be therefore hypothesized to occur in order to sustain cell viability in conditions of nitrooxidative stress. However, if GSNOR is a direct target of Nrf2 still waits to be demonstrated.
Conflict of Interests
The authors state that no conflict of interests does exist.
Salvatore Rizza and Claudia Cirotti equally contributed to this work.
The authors would like to thank Professor Jonathan S. Stamler for kindly providing them with the GSNOR-KO mouse strains. This work has been supported by grants from the Italian Ministry of Health, Young Italian Researcher Grant (GR-2008-1138121), the Italian Association for Cancer Research, AIRC-MFAG 2011 (11452), and the Danish Cancer Society (KBVU R72-A4408 and KBVU R72-A4647). The authors are also grateful to the Bjarne Saxhof Foundation, Lundbeck Foundation (R167-2013-16100), and Novo Nordisk (7559) to have sustained this research.
- T. Nakamura and S. A. Lipton, “S-nitrosylation of critical protein thiols mediates protein misfolding and mitochondrial dysfunction in neurodegenerative diseases,” Antioxidants and Redox Signaling, vol. 14, no. 8, pp. 1479–1492, 2011.
- K. J. Barnham, C. L. Masters, and A. I. Bush, “Neurodegenerative diseases and oxidatives stress,” Nature Reviews Drug Discovery, vol. 3, no. 3, pp. 205–214, 2004.
- M. T. Lin and M. F. Beal, “Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases,” Nature, vol. 443, no. 7113, pp. 787–795, 2006.
- S. H. Appel, D. R. Beers, and J. S. Henkel, “T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?” Trends in Immunology, vol. 31, no. 1, pp. 7–17, 2010.
- B. Thomas and M. Flint Beal, “Parkinson's disease,” Human Molecular Genetics, vol. 16, no. 2, pp. R183–R194, 2007.
- E.-K. Tan and L. M. Skipper, “Pathogenic mutations in Parkinson disease,” Human Mutation, vol. 28, no. 7, pp. 641–653, 2007.
- D. T. Hess, A. Matsumoto, S.-O. Kim, H. E. Marshall, and J. S. Stamler, “Protein S-nitrosylation: purview and parameters,” Nature Reviews Molecular Cell Biology, vol. 6, no. 2, pp. 150–166, 2005.
- M. A. Wilson, “The role of cysteine oxidation in DJ-1 function and dysfunction,” Antioxidants and Redox Signaling, vol. 15, no. 1, pp. 111–122, 2011.
- G. Ito, H. Ariga, Y. Nakagawa, and T. Iwatsubo, “Roles of distinct cysteine residues in S-nitrosylation and dimerization of DJ-1,” Biochemical and Biophysical Research Communications, vol. 339, no. 2, pp. 667–672, 2006.
- J.-Y. Im, K.-W. Lee, J.-M. Woo, E. Junn, and M. M. Mouradian, “Dj-1 induces thioredoxin 1 expression through the Nrf2 pathway,” Human Molecular Genetics, vol. 21, no. 13, pp. 3013–3024, 2012.
- C. M. Clements, R. S. McNally, B. J. Conti, T. W. Mak, and J. P.-Y. Ting, “DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 41, pp. 15091–15096, 2006.
- M. I. Ivanova, S. A. Sievers, E. L. Guenther et al., “Aggregation-triggering segments of SOD1 fibril formation support a common pathway for familial and sporadic ALS,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 1, pp. 197–201, 2014.
- C. Bendotti and M. T. Carrì, “Lessons from models of SOD1-linked familial ALS,” Trends in Molecular Medicine, vol. 10, no. 8, pp. 393–400, 2004.
- L. Wang, B. Popko, and R. P. Roos, “An enhanced integrated stress response ameliorates mutant SOD1-induced ALS,” Human Molecular Genetics, vol. 23, no. 10, Article ID ddt658, pp. 2629–2638, 2014.
- L. G. Bilsland, E. Sahai, G. Kelly, M. Golding, L. Greensmith, and G. Schiavo, “Deficits in axonal transport precede ALS symptoms in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 47, pp. 20523–20528, 2010.
- A. I. Bartha, A. Foster-Barber, S. P. Miller et al., “Neonatal encephalopathy: association of cytokines with MR spectroscopy and outcome,” Pediatric Research, vol. 56, no. 6, pp. 960–966, 2004.
- C. C. Chiueh, “Neuroprotective properties of nitric oxide,” Annals of the New York Academy of Sciences, vol. 890, pp. 301–311, 1999.
- J. J. Hedberg, W. J. Griffiths, S. J. F. Nilsson, and J. O. Hoog, “Reduction of S-nitrosoglutathione by human alcohol dehydrogenase 3 is an irreversible reaction as analysed by electrospray mass spectrometry,” European Journal of Biochemistry, vol. 270, no. 6, pp. 1249–1256, 2003.
- Z. Yang, Z.-E. Wang, P.-T. Doulias et al., “Lymphocyte development requires S-nitrosoglutathione reductase,” The Journal of Immunology, vol. 185, no. 11, pp. 6664–6669, 2010.
- L. Liu, Y. Yan, M. Zeng et al., “Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock,” Cell, vol. 116, no. 4, pp. 617–628, 2004.
- J. Leung, W. Wei, and L. Liu, “S-nitrosoglutathione reductase deficiency increases mutagenesis from alkylation in mouse liver,” Carcinogenesis, vol. 34, no. 5, pp. 984–989, 2013.
- W. Wei, B. Li, M. A. Hanes, S. Kakar, X. Chen, and L. Liu, “S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis,” Science Translational Medicine, vol. 2, no. 19, article 19ra13, 2010.
- C. Montagna, G. Di Giacomo, S. Rizza et al., “S-nitrosoglutathione reductase deficiency-induced S-nitrosylation results in neuromuscular dysfunction,” Antioxidants & Redox Signaling, vol. 21, no. 4, pp. 570–587, 2014.
- L. Liu, A. Hausladen, M. Zeng, L. Que, J. Heitman, and J. S. Stamler, “A metabolic enzyme for S-nitrosothiol conserved from bacteria to humans,” Nature, vol. 410, no. 6827, pp. 490–494, 2001.
- M. R. Ciriolo, A. Battistoni, M. Falconi, G. Filomeni, and G. Rotilio, “Role of the electrostatic loop of Cu,Zn superoxide dismutase in the copper uptake process,” European Journal of Biochemistry, vol. 268, no. 3, pp. 737–742, 2001.
- X. Liu and F. Fagotto, “A method to separate nuclear, cytosolic, and membrane-associated signaling molecules in cultured cells,” Science Signaling, vol. 4, no. 203, article pl2, 2011.
- M. T. Forrester, M. W. Foster, M. Benhar, and J. S. Stamler, “Detection of protein S-nitrosylation with the biotin-switch technique,” Free Radical Biology and Medicine, vol. 46, no. 2, pp. 119–126, 2009.
- F. Liu, J. L. Nguyen, J. D. Hulleman, L. Li, and J.-C. Rochet, “Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease,” Journal of Neurochemistry, vol. 105, no. 6, pp. 2435–2453, 2008.
- H. Aleyasin, M. W. C. Rousseaux, P. C. Marcogliese et al., “DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 7, pp. 3186–3191, 2010.
- M. R. Ciriolo, A. de Martino, E. Lafavia, L. Rossi, M. T. Carrì, and G. Rotilio, “Cu,Zn-superoxide dismutase-dependent apoptosis induced by nitric oxide in neuronal cells,” The Journal of Biological Chemistry, vol. 275, no. 7, pp. 5065–5072, 2000.
Copyright © 2015 Salvatore Rizza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.